Basilea Competitors

Pink Sheets . USA . 
Stock . Basilea Pharmaceutica AG
BPMUF Stock  USD 52.83  0.00  0.00%   
Basilea Pharmaceutica competes with Reviva Pharmaceuticals, Protalix Biotherapeutics, Eyepoint Pharmaceuticals, Sellas Life, and ProQR Therapeutics; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Basilea Pharmaceutica competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Basilea Pharmaceutica to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Basilea Pharmaceutica Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Basilea Pharmaceutica competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Basilea Pharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
52.4452.8353.22
Details
Intrinsic
Valuation
LowRealHigh
47.5561.8862.27
Details
Naive
Forecast
LowNextHigh
52.8953.2853.66
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
52.8352.8352.83
Details

Basilea Pharmaceutica Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Basilea Pharmaceutica and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Basilea and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Basilea Pharmaceutica does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
WVE
+ 0.94
PRQR
APLS
+ 0.8
OCUP
PRQR
+ 0.75
EYPT
WVE
+ 0.73
EYPT
WVE
+ 0.58
PLX
PRQR
+ 0.57
PLX
  
High negative correlations   
APLS
- 0.71
WVE
ALNY
- 0.57
PLX
WVE
- 0.55
OCUP
APLS
- 0.53
PRQR
BPMC
- 0.45
RVPH
PLX
- 0.44
OCUP

Risk-Adjusted Indicators

There is a big difference between Basilea Pink Sheet performing well and Basilea Pharmaceutica Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Basilea Pharmaceutica's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
OCUP  3.18 (0.79) 0.00 (3.04) 0.00 
 0.00 
 6.10 
(5.84)
 27.18 
RVPH  4.80  0.55  0.04 (0.35) 5.82 
(5.53)
 10.71 
(9.86)
 40.06 
PLX  3.15  1.10  0.27 (1.33) 2.38 
(4.25)
 10.00 
(5.56)
 20.38 
EYPT  3.86 (0.29)(0.01) 0.03  4.25 
(4.66)
 8.03 
(7.35)
 40.16 
SLS  2.25 (0.12) 0.00 (0.89) 0.00 
 0.00 
 5.60 
(4.00)
 17.74 
PRQR  5.14  1.08  0.42  0.45  2.38 
(9.65)
 7.14 
(4.95)
 129.77 
ALNY  1.70 (0.23) 0.00 (0.05) 0.00 
 0.00 
 2.91 
(3.88)
 13.26 
WVE  5.81  1.54  0.47  0.56  3.11 
(8.73)
 10.86 
(6.00)
 82.93 
BPMC  1.83 (0.14)(0.04) 0.01  2.57 
(1.75)
 4.90 
(3.62)
 14.28 
APLS  2.44 (0.34) 0.00 (0.35) 0.00 
 0.00 
 4.31 
(5.17)
 15.97 
All Fundamental Data

Basilea Pharmaceutica Competitive Analysis

The better you understand Basilea Pharmaceutica competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Basilea Pharmaceutica's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Basilea Pharmaceutica's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BPMUF OCUP RVPH PLX EYPT SLS PRQR ALNY WVE BPMC
 0.00 
 52.83 
Basilea
 5.04 
 1.13 
Ocuphire
 2.61 
 1.12 
Reviva
 1.75 
 1.68 
Protalix
 2.49 
 9.00 
Eyepoint
 2.50 
 1.17 
Sellas
 2.82 
 3.44 
ProQR
 0.94 
 253.35 
Alnylam
 0.40 
 14.83 
Wave
 0.81 
 94.63 
Blueprint
Market Volatility
(90 Days Market Risk)
Very steady
Dangerous
Very risky
Dangerous
Somewhat reliable
Risky
Abnormally volatile
Very steady
Unstable
Very steady
Market Performance
(90 Days Performance)
OK
Very Weak
Insignificant
Solid
Weak
Very Weak
OK
Very Weak
Good
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Dangerous
Very High
About Average
Low
Low
Low
Low
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Hold
Buy
Cautious Hold
Current Ratio
1.36
5.41
6.72
1.33
6.16
2.36
5.93
3.48
2.5
6.0
Net Asset
247.27 M
53.95 M
23.7 M
84.43 M
355.18 M
6.22 M
138 M
3.83 B
274.95 M
1.05 B
Profit Margin
0.0056
-0.86
N/A
-0.39
-2.27
N/A
-1.3
-0.16
-2.66
-0.29
EBITDA
2.11 M
(10.56 M)
(10.1 M)
11.65 M
(69 M)
529 K
(24.1 M)
(258.24 M)
(58.79 M)
(470.36 M)
Operating Margin
0.0635
-7.49
N/A
-0.18
-3.11
N/A
-2.19
-0.15
8.33
-0.38
Current Valuation
724.26 M
(6.57 M)
31.98 M
104.19 M
398.09 M
61.89 M
289.12 M
31.2 B
1.98 B
5.75 B
Price To Book
N/A
0.86
8.35
3.88
2.88
5.18
13.96
1009.99
15.97
19.2
Retained Earnings
(908 M)
(81.47 M)
(134.35 M)
(381.55 M)
(742.15 M)
(217.24 M)
(400.85 M)
(7.01 B)
(1.02 B)
(2.34 B)
Current Asset
283 M
N/A
N/A
59.65 M
15.08 M
N/A
97.77 M
1.11 B
161.38 M
170.42 M
Beta
0.88
0.31
-0.055
0.67
1.52
2.4
0.25
0.39
-1.21
0.59
Number Of Employees
177
14
15
208
121
16
156
2.1 K
266
638
Shares Outstanding
11.93 M
26.2 M
33.44 M
73.63 M
68.25 M
70.38 M
105.91 M
128.98 M
152.52 M
63.53 M
Cash Flow From Operations
(32.02 M)
(1.11 M)
(28.32 M)
(1.32 M)
1.88 M
(31.41 M)
21.55 M
104.16 M
(19.43 M)
(436.85 M)
Total Debt
94.54 M
4.04 M
17.98 M
26.28 M
4.91 M
906 K
19.73 M
2.68 B
32.12 M
774.12 M
Return On Equity
N/A
-0.36
-17.95
-0.43
-0.75
-8.88
-0.67
-15.01
-2.44
-0.5
Z Score
-0.6
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0261
-0.21
-2.34
-0.1
-0.31
-1.29
-0.15
-0.0292
-0.34
-0.15
Book Value Per Share
-5.67
1.56
0.21
0.46
4.09
-0.25
0.31
0.25
0.95
4.93
Number Of Shares Shorted
N/A
930.64 K
5.3 M
3.1 M
9.68 M
8.61 M
677.63 K
3.7 M
6.82 M
4.13 M
Current Liabilities
64 M
N/A
N/A
10.33 M
11.26 M
N/A
5.49 M
62.1 M
3.82 M
18.64 M
Total Asset
247.27 M
53.95 M
23.7 M
84.43 M
355.18 M
6.22 M
138 M
3.83 B
274.95 M
1.05 B
Debt To Equity
N/A
0.012
N/A
N/A
0.3
0.059
0.7
5.63
1.02
0.14
Short Ratio
N/A
10.1
19.04
22.71
10.4
14.07
0.12
3.94
2.99
5.59
Target Price
N/A
16.75
15.2
14.0
33.45
5.83
7.4
301.21
22.3
125.58
Shares Owned By Institutions
29.13
10.44
30.06
5.2
93.43
7.36
24.9
98.05
78.48
99.1
Market Capitalization
626.06 M
34.84 M
37.45 M
123.7 M
614.26 M
84.46 M
364.32 M
32.68 B
2.26 B
6.01 B
Price To Earning
200.0
N/A
N/A
-1.23
-2.82
N/A
-1.97
-22.92
-6.5
7.93
Price To Earnings To Growth
N/A
N/A
N/A
-0.1
N/A
N/A
N/A
-0.49
N/A
N/A
Price To Sales
4.09
2.12
N/A
3.25
13.44
26.9
19.82
15.6
42.19
13.84
Net Income
(6.83 M)
(9.99 M)
(39.26 M)
8.31 M
(70.8 M)
(37.34 M)
(27.54 M)
(440.24 M)
(57.51 M)
(506.98 M)
Earnings Per Share
0.25
-0.54
-1.08
-0.15
-1.99
-0.67
-0.31
-2.61
-1.12
-2.09
Shares Owned By Insiders
3.07
7.33
14.78
14.53
1.14
0.24
14.49
0.42
15.03
0.9
Revenue
148.12 M
19.05 M
N/A
65.49 M
46.02 M
N/A
6.51 M
1.83 B
113.31 M
249.38 M
Working Capital
219 M
49.91 M
6.53 M
24.4 M
281.54 M
(10.56 M)
86.78 M
2.01 B
48.93 M
593.47 M
Cash And Equivalents
140.74 M
17.15 M
23.19 M
17.11 M
171.17 M
26.99 M
156.4 M
2.27 B
148.16 M
853.11 M
Cash Per Share
11.89
0.83
1.13
0.41
5.02
1.31
2.19
18.41
1.71
14.28
Gross Profit
30.89 M
(14.58 M)
N/A
28.05 M
26.95 M
900 K
4.8 M
868.6 M
(73.64 M)
177.28 M
Day Typical Price
52.83
1.14
1.12
1.69
9.16
1.18
3.45
251.61
14.87
93.9
Accumulation Distribution
N/A
0.0833
0.0603
0.0462
0.0558
0.0333
0.048
0.0235
0.0587
0.0369
Market Facilitation Index
N/A
0.1
0.07
0.08
0.53
0.04
0.17
5.97
0.9
3.52
Daily Balance Of Power
0.0
(0.60)
(0.43)
(0.38)
(0.43)
(0.75)
(0.59)
0.397
(0.07)
0.2159
Period Momentum Indicator
N/A
(0.06)
(0.03)
(0.03)
(0.23)
(0.03)
(0.10)
2.37
(0.06)
0.76
Rate Of Daily Change
1.0
0.95
0.97
0.98
0.98
0.98
0.97
1.01
1.0
1.01
Day Median Price
52.83
1.15
1.13
1.69
9.24
1.18
3.46
250.75
14.89
93.54
Price Action Indicator
N/A
(0.05)
(0.02)
(0.03)
(0.35)
(0.03)
(0.07)
3.79
(0.09)
1.47
Relative Strength Index
100.0
34.29
34.69
85.03
63.3
46.15
63.97
23.61
46.23
81.53
Coefficient Of Variation
812.4
(595.44)
1670.87
450.74
5422.6
(3,177)
1046.67
(4,045)
610.83
10302.25
Mean Deviation
0.0914
3.18
4.8
3.15
3.86
2.25
5.14
1.7
5.81
1.83
Jensen Alpha
0.0331
(0.79)
0.5489
1.1
(0.29)
(0.12)
1.08
(0.23)
1.54
(0.14)
Total Risk Alpha
(0.02)
(1.46)
(0.69)
0.2843
(0.82)
(0.60)
(0.97)
(0.46)
0.0649
(0.39)
Sortino Ratio
N/A
N/A
0.0445
0.2731
(0.01)
N/A
0.4236
N/A
0.4737
(0.04)
Downside Variance
N/A
N/A
41.64
10.48
18.64
N/A
10.14
N/A
15.2
7.12
Standard Deviation
0.377
4.47
6.98
4.57
5.82
3.11
15.49
2.47
12.08
2.55
Kurtosis
66.0
6.04
5.83
3.55
7.44
2.67
58.98
3.44
23.89
1.18
Potential Upside
N/A
6.1
10.71
10.0
8.03
5.6
7.14
2.91
10.86
4.9
Treynor Ratio
1.33
(3.04)
(0.35)
(1.33)
0.0304
(0.89)
0.453
(0.05)
0.5556
0.0118
Maximum Drawdown
3.06
27.18
40.06
20.38
40.16
17.74
129.77
13.26
82.93
14.28
Variance
0.1421
19.94
48.71
20.91
33.89
9.64
239.8
6.09
145.92
6.5
Market Risk Adjusted Performance
1.34
(3.03)
(0.34)
(1.32)
0.0404
(0.88)
0.463
(0.04)
0.5656
0.0218
Risk Adjusted Performance
0.0838
(0.12)
0.0547
0.1779
0.0228
(0.02)
0.0825
(0.01)
0.1345
0.0144
Skewness
8.12
(1.36)
1.12
1.5
1.9
1.13
7.49
(0.99)
4.57
0.1812
Semi Deviation
N/A
N/A
5.82
2.38
4.25
N/A
2.38
N/A
3.11
2.57
Information Ratio
(0.22)
(0.20)
0.0412
0.1933
(0)
(0.07)
0.0871
(0.08)
0.1529
(0.04)
Value At Risk
N/A
(5.84)
(9.86)
(5.56)
(7.35)
(4.00)
(4.95)
(3.88)
(6.00)
(3.62)
Expected Short fall
N/A
N/A
(5.53)
(4.25)
(4.66)
N/A
(9.65)
N/A
(8.73)
(1.75)
Downside Deviation
N/A
N/A
6.45
3.24
4.32
N/A
3.18
N/A
3.9
2.67
Semi Variance
N/A
N/A
33.87
5.67
18.03
N/A
5.68
N/A
9.68
6.62

Basilea Pharmaceutica Competition Performance Charts

Five steps to successful analysis of Basilea Pharmaceutica Competition

Basilea Pharmaceutica's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Basilea Pharmaceutica in relation to its competition. Basilea Pharmaceutica's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Basilea Pharmaceutica in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Basilea Pharmaceutica's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Basilea Pharmaceutica, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Basilea Pharmaceutica position

In addition to having Basilea Pharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Stores Thematic Idea Now

Stores
Stores Theme
Companies providing different types of retail and wholesale services. The Stores theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Stores Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Basilea Pink Sheet

Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY